Bill Haney, Dragonfly Therapeutics CEO (Photo by Dave Pedley/Getty Images for SXSW)
May 2, 2022 08:30 AM EDT
Deals
Bioregnum

Gilead joins a line­up of Big Phar­ma part­ners bet­ting big on TriN­KETs, with a $300M cash ante to get start­ed on a 5T4

John Carroll

Editor & Founder

Bill Haney’s Drag­on­fly Ther­a­peu­tics is mak­ing the vault be­tween biotech start­up and the next big lev­el: adding clin­i­cal-stage com­pounds to its own fledg­ling pipeline while …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times